Corcept Therapeutics에 대한 매도 수량은 투자자에게 Corcept Therapeutics의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Corcept Therapeutics (NASDAQ:CORT) 주식, 공매도 수량 보고

CORCEPT THERAPEUTICS INC

Corcept Therapeutics

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

Pattaya,,Thailand,-,Circa,April,,2023:,Entrance,To,Calvin,Klein

Mid Cap

News

Movers

Trading Ideas

CELH

COOP

CORT

LOAR

PRGS

VRRM

지난주 상위 중형주를 추적하는 S&amp;P400 지수는 9.1% 하락했고, 특히 금요일에만 4.8% 급락했다. 그러나 이러한 매도세 속에도 시장 흐름을 역행하며 상승한 중형주는 다음과 같다.

굿이어·램웨스턴 등 지난주 S&amp;P 400 급락에도 상승한 중형주 9종목 (3월 31일~4월 4일)

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics Inc

CORTS Trust for Bellsouth 7.00% CorTS Ctfs due 12/01/2095

CORTELCO SYS PUERTO RICO by Cortelco Systems Puerto Rico Inc.

Cortelco Systems Puerto Rico Inc

Corteva Inc

Cortex

Structures Products Cp 8% CorTS Issued by Peco Energy Cap Tr II Preferred Stock

Corts Trust Peco Energy Capital Trust III

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) has outperformed the market over the past 5 years by 23.49% on an annualized basis producing an average annual return of 38.6%. Currently, Corcept Therapeutics has a market capitalization of $7.63 billion. 
Buying $100 In CORT: If an investor had bought $100 of CORT stock 5 years ago, it would be worth $524.96 today based on a price of $71.92 for CORT at the time of writing.
<h3>Corcept Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747059311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years

Corcept Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NYSE">CORT</a>) short percent of float has fallen 25.63% since its last report. The company recently reported that it has 12.29 million shares sold short, which is 16.31% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.11 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Corcept Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746820856_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Corcept Therapeutics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Corcept Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Corcept Therapeutics's peer group average for short interest as a percentage of float is 2.83%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Corcept Therapeutics?

Ratings for Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Corcept Therapeutics, presenting an average target of $122.89, a high estimate of $150.00, and a low estimate of $78.00. Marking an increase of 17.53%, the current average surpasses the previous average price target of $104.56. 
<img src="https://www.benzinga.com/files/images/story/2025/1746536555_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Corcept Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$131.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Edward Nash</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$142.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Corcept Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Corcept Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Corcept Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Corcept Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CORT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Corcept Therapeutics analyst ratings.</a>
<h2>About Corcept Therapeutics</h2>
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
<h3>Corcept Therapeutics: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Corcept Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 34.33% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Corcept Therapeutics's net margin excels beyond industry benchmarks, reaching 16.71%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Corcept Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of 4.61%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.74%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing Corcept Therapeutics: Insights From 9 Financial Analysts

WIIM

Corcept Therapeutics shares are trading lower after the company reported worse-than-expected Q1 sales results. Also, HC Wainwright maintained a Buy rating on the stock but lowered its price target from $150 to $145.

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and lowers the price target from $150 to $145.

Price Target

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Lowers Price Target to $145

<h3>Gainers</h3>
<ul>
<li>Rafael Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) shares increased by 21.7% to $1.74 during Monday's after-market session. The market value of their outstanding shares is at $63.8 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares rose 17.73% to $1.66. The market value of their outstanding shares is at $22.8 million. </li>
<li>SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) shares moved upwards by 14.45% to $16.31. The market value of their outstanding shares is at $693.6 million. As per the news, the Q1 earnings report came out today. </li>
<li>Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) shares rose 11.79% to $122.7. The market value of their outstanding shares is at $12.2 billion. The company's, Q1 earnings came out today. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock increased by 11.76% to $0.19. The market value of their outstanding shares is at $4.0 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock increased by 11.27% to $0.21. The market value of their outstanding shares is at $5.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 22.2% to $0.86 during Monday's after-market session. The company's market cap stands at $5.1 million. </li>
<li>Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) stock declined by 15.0% to $11.85. The company's market cap stands at $280.4 million. As per the press release, Q1 earnings came out today. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock fell 9.24% to $0.85. The market value of their outstanding shares is at $60.7 million. </li>
<li>HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) stock decreased by 8.13% to $30.54. The market value of their outstanding shares is at $932.2 million. As per the news, the Q1 earnings report came out today. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock fell 8.12% to $3.01. The market value of their outstanding shares is at $78.3 million. </li>
<li>Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) stock declined by 8.05% to $67.99. The company's market cap stands at $7.2 billion. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTOR

GCTK

HSTM

NBIX

NCNA

OGEN

SIBN

SNTI

SXTC

TCMD

12 Health Care Stocks Moving In Monday's After-Market Session

Corcept Therapeutics shares are trading lower after the company reported a Q1 sales miss.

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) affirms FY2025 sales outlook from $900.00 million-$950.00 million to $900.00 million-$950.00 million vs $905.38 million estimate.

Guidance

Corcept Therapeutics Affirms FY2025 Sales Guidance of $900.00M-$950.00M vs $905.38M Est

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.14 by 21.43 percent. This is a 32 percent decrease over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $157.21 million which missed the analyst consensus estimate of $177.94 million by 11.65 percent. This is a 7.09 percent increase over sales of $146.81 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Corcept Therapeutics Q1 EPS $0.17 Beats $0.14 Estimate, Sales $157.21M Miss $177.94M Estimate

ACEL

ADEA

ADUS

AESI

AMRC

AOMR

AORT

ARES

AROC

AXSM

BCRX

BCSF

BFAM

BNTX

BRBR

BRCC

BWXT

CERT

CRBG

CRGY

CSTL

CTRA

DENN

DMRC

DORM

EKSO

ESCA

EVER

FANG

FRPT

GBDC

GECC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSIC

HSII

IART

ICHR

INSP

IPAR

IRMD

JBTM

JELD

JRVR

LSCC

MATX

MYPS

NGVT

NMFC

NSSC

NVTS

OCUL

OPAD

OTTR

PLMR

PLOW

PLTR

PLYA

PRAA

PRIM

RAIL

RAND

Earnings Scheduled For May 5, 2025

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) has outperformed the market over the past 10 years by 18.46% on an annualized basis producing an average annual return of 28.66%. Currently, Corcept Therapeutics has a market capitalization of $7.52 billion. 
Buying $1000 In CORT: If an investor had bought $1000 of CORT stock 10 years ago, it would be worth $11,852.89 today based on a price of $71.25 for CORT at the time of writing.
<h3>Corcept Therapeutics's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745622011_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Corcept Therapeutics 10 Years Ago Would Be Worth Today

Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data will be presented in a late-breaking oral presentation on Monday, June 2, 2025.
<ul>
<li>Title: ROSELLA: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer​ (GOG-3073, ENGOT-ov72)</li>
<li>Oral Abstract Session – Gynecologic Cancer</li>
<li>June 2, 2025, 8:00 AM – 11:00 AM CDT</li>
<li>Abstract Number: LBA5507</li>
</ul>
The ROSELLA trial is being conducted in collaboration with The GOG Foundation, Inc. (GOG-F), the European Network of Gynaecological Oncological Trial groups (ENGOT), the Asia-Pacific Gynecologic Oncology Trials Group (APGOT), the Latin American Cooperative Oncology Group (LACOG) and the Australia New Zealand Gynaecological Oncology Group (ANZGOG).

Biotech

General

Corcept To Present Late-Breaking Data From Pivotal Phase 3 ROSELLA Trial Of Relacorilant In Platinum-Resistant Ovarian Cancer At ASCO 2025

Hypercortisolism identified in 24 percent of patients with difficult-to-control type 2 diabetes
Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the publication of findings from the prevalence phase of the CATALYST trial in Diabetes Care, a peer-reviewed journal published by the American Diabetes Association.
The publication, Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes, can be accessed at: <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fdiabetesjournals.org%2Fcare%2Flookup%2Fdoi%2F10.2337%2Fdc24-2841&amp;esheet=54240352&amp;newsitemid=20250421854008&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdiabetesjournals.org%2Fcare%2Flookup%2Fdoi%2F10.2337%2Fdc24-2841&amp;index=1&amp;md5=93462c6dd5567a9a85f2e87e65dc5785">https://diabetesjournals.org/care/lookup/doi/10.2337/dc24-2841</a>.
CATALYST was the largest and most rigorous trial ever conducted to assess the prevalence of hypercortisolism (Cushing's syndrome) in patients with difficult-to-control type 2 diabetes. Part one of the study screened 1,057 patients at 36 sites across the United States. All patients had hemoglobin A1c greater than 7.5 percent, despite receiving multiple glucose-lowering therapies, including GLP-1 receptor agonists. Using a simple, standardized 1-mg dexamethasone suppression test (DST), 24 percent of these patients were found to have hypercortisolism. These findings were first presented at the American Diabetes Association Scientific Sessions in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.corcept.com%2Fnews-releases%2Fnews-release-details%2Fcorcept-announces-presentation-results-prevalence-phase-catalyst&amp;esheet=54240352&amp;newsitemid=20250421854008&amp;lan=en-US&amp;anchor=June+2024&amp;index=2&amp;md5=12702a0e0a0fa0edd714c70e67cb4916">June 2024</a>.

Corcept Therapeutics Announces Publication Of Findings From Prevalence Phase Of CATALYST Trial In Diabetes Care

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) has outperformed the market over the past 20 years by 7.21% on an annualized basis producing an average annual return of 15.13%. Currently, Corcept Therapeutics has a market capitalization of $7.34 billion. 
Buying $1000 In CORT: If an investor had bought $1000 of CORT stock 20 years ago, it would be worth $16,746.85 today based on a price of $69.59 for CORT at the time of writing.
<h3>Corcept Therapeutics's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744818312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth This Much Today

Corcept Begins Trial Of Relacorilant Plus Nab-Paclitaxel And Bevacizumab For Patients With Platinum-Resistant Ovarian Cancer

The S&amp;P400 index, which tracks the top mid-cap stocks, fell 9.1% last week and 4.8% last Friday. However, these mid-cap stocks emerged as winners. Are they in your portfolio?
<ol>
<li>Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) shares surged 36.28% after the company disclosed that the ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer met its primary endpoint of improved progression-free survival, as assessed by blinded <a href="https://www.benzinga.com//node/44569564" target="_blank" rel="noreferrer noopener">independent central review (PFS-BICR)</a>.</li>
<li>Mr. Cooper Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) stock escalated 28.44% after the company announced Rocket Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) will acquire it in <a href="https://www.benzinga.com//node/44565671" target="_blank" rel="noreferrer noopener">a $9.4 billion all-stock deal</a>.</li>
<li>Verra Mobility Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRRM#NASDAQ">VRRM</a>) shares rose 10.90%.</li>
<li>Goodyear Tire &amp; Rubber Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>) stock rose 10.35% after Deutsche Bank upgraded it from Hold to Buy <a href="https://www.benzinga.com/quote/gt/analyst-ratings" target="_blank" rel="noreferrer noopener">and announced a $13 price forecast</a>.</li>
<li>Progress Software Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) stock upped 9.30% after the company reported better-than-expected <a href="https://www.benzinga.com//node/44570749" target="_blank" rel="noreferrer noopener">first-quarter financial results</a>.</li>
<li>Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) stock rose 9.24% after the company reported better-than-expected third-quarter financial results and issued <a href="https://www.benzinga.com//node/44629158" target="_blank" rel="noreferrer noopener">FY25 sales guidance above estimates</a>.</li>
<li>Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) stock rose 5.62%.</li>
<li>Loar Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>) shares increased 5.26% after the <a href="https://www.benzinga.com//node/44560215" target="_blank" rel="noreferrer noopener">company reported quarterly results</a>.</li>
<li>PVH Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) shares gained 4.68% last week following strong <a href="https://www.benzinga.com//node/44572437" target="_blank" rel="noreferrer noopener">Q4 financial results</a> and the announcement of plans to enter into a $500 million accelerated share repurchase program.</li>
</ol>
Photo by Sorbis via Shutterstock

How Some Mid Cap Stocks Outshone The S&P 400's Dramatic Drop Last Week (Mar 31-Apr 4)

Piper Sandler analyst David Amsellem maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Overweight and raises the price target from $128 to $131.

Piper Sandler Maintains Overweight on Corcept Therapeutics, Raises Price Target to $131

<h3>Gainers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock moved upwards by 488.1% to $2.12 during Tuesday's regular session. The market value of their outstanding shares is at $7.0 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock increased by 236.5% to $0.87. The market value of their outstanding shares is at $13.6 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Alaunos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) shares moved upwards by 55.1% to $2.28. The market value of their outstanding shares is at $3.6 million. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares moved upwards by 53.55% to $72.22. The market value of their outstanding shares is at $392.6 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares moved upwards by 39.56% to $0.6. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock moved upwards by 37.91% to $0.32. The company's market cap stands at $1.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) shares declined by 32.3% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $30.0 million. The company's, Q4 earnings came out yesterday. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares decreased by 29.88% to $2.88. The market value of their outstanding shares is at $43.7 million. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) stock decreased by 24.23% to $0.23. The company's market cap stands at $9.8 million. </li>
<li>Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) stock declined by 18.67% to $92.9. The company's market cap stands at $9.8 billion. </li>
<li>Citius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) shares decreased by 18.13% to $1.22. The market value of their outstanding shares is at $10.4 million. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) shares declined by 17.7% to $5.07. The company's market cap stands at $80.4 million. As per the news, the Q4 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIAF

CARM

CTXR

ELTX

HEPA

NUTX

RSLS

RVPH

TCRT

YCBD

12 Health Care Stocks Moving In Tuesday's Intraday Session

Investors with a lot of money to spend have taken a bearish stance on Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CORT, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Corcept Therapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 13% bullish and 73%, bearish.
Out of all of the special options we uncovered, 11 are puts, for a total amount of $599,257, and 4 are calls, for a total amount of $1,067,250.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $65.0 and $115.0 for Corcept Therapeutics, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Corcept Therapeutics's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Corcept Therapeutics's substantial trades, within a strike price spectrum from $65.0 to $115.0 over the preceding 30 days.
<h3>Corcept Therapeutics 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743522331_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CORT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$33.4</td>
<td>$31.4</td>
<td>$32.8</td>
<td>$65.00</td>
<td>$984.0K</td>
<td>1.7K</td>
<td align="right">310</td>
</tr>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$9.0</td>
<td>$8.1</td>
<td>$8.8</td>
<td>$100.00</td>
<td>$88.0K</td>
<td>556</td>
<td align="right">520</td>
</tr>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$29.4</td>
<td>$28.1</td>
<td>$29.76</td>
<td>$100.00</td>
<td>$74.1K</td>
<td>0</td>
<td align="right">53</td>
</tr>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$29.0</td>
<td>$25.8</td>
<td>$28.5</td>
<td>$100.00</td>
<td>$70.6K</td>
<td>0</td>
<td align="right">0</td>
</tr>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$7.4</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$100.00</td>
<td>$70.0K</td>
<td>556</td>
<td align="right">160</td>
</tr>
</tbody>
</table>

<h3>About Corcept Therapeutics</h3>
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Following our analysis of the options activities associated with Corcept Therapeutics, we pivot to a closer look at the company's own performance.
<h3>Current Position of Corcept Therapeutics</h3>
<ul>
<li>With a trading volume of 3,215,057, the price of CORT is up by 0.53%, reaching $114.82.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 29 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Corcept Therapeutics</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $147.33.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Canaccord Genuity persists with their Buy rating on Corcept Therapeutics, maintaining a target price of $142. 
&#x2A; An analyst from HC Wainwright &amp; Co. persists with their Buy rating on Corcept Therapeutics, maintaining a target price of $150. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Corcept Therapeutics, targeting a price of $150. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Corcept Therapeutics with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

Corcept Therapeutics Unusual Options Activity For April 01

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and raises the price target from $130 to $142.

Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $142

Press Releases

FDA Files Corcept's New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL

CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Comments

Corcept Therapeutics

매도 수량

Corcept Therapeutics (NASDAQ:CORT) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌